Discounts eat into Lilly's bottom line in third quarter

23 October 2019

In New York, shares in American drugmaker Eli Lilly (NYSE: LLY) fell almost 4% by mid-morning on Wednesday, after a third quarter results statement revealed the firm had missed sales expectations amid steep discounts for diabetes drug Trulicity (dulaglutide).

Revenue for the third quarter was $5.5 billion, up 3% from the same period of 2018. Reported net income, following Generally Accepted Accounting Principles (GAAP), was $1.3 billion, a 9% increase.

Partly due to a reduced tax burden, profits were better than expected for the quarter. The earnings per share (EPS) figure was up 22% at $1.37. Lilly raised its EPS expectations for the full year to between $5.75 and $5.85, up from $5.67 to $5.77.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK